iRegene
iRegene is a biotechnology company focused on developing first-in-class therapies for major incurable diseases, particularly neurodegenerative and rare diseases. Their business model centers on pharmaceutical therapy development using advanced AI-powered discovery platforms including omics analysis, virtual screening, gene editing, and exosome design for therapeutic delivery. They have multiple clinical-stage projects targeting Parkinson's disease, early-onset Parkinson's, multiple system atrophy, retinal degenerative diseases, and ischemic stroke, with trials ongoing in China and the US. iRegene aims to make fast-acting, disease-reversing therapies widely accessible, leveraging a next-generation R&D ecosystem to accelerate drug discovery and validation.
iRegene
iRegene is a biotechnology company focused on developing first-in-class therapies for major incurable diseases, particularly neurodegenerative and rare diseases. Their business model centers on pharmaceutical therapy development using advanced AI-powered discovery platforms including omics analysis, virtual screening, gene editing, and exosome design for therapeutic delivery. They have multiple clinical-stage projects targeting Parkinson's disease, early-onset Parkinson's, multiple system atrophy, retinal degenerative diseases, and ischemic stroke, with trials ongoing in China and the US. iRegene aims to make fast-acting, disease-reversing therapies widely accessible, leveraging a next-generation R&D ecosystem to accelerate drug discovery and validation.